Back to today’s briefing

Story perspectives

Eli Lilly's Weight Loss Pill Surpasses Competitors Amid Safety Concerns

2/26/2026

25 5 Full Breakdown

Summary

Story summary

Eli Lilly's GLP-1 pill orforglipron achieved greater weight loss than semaglutide in a clinical trial, up to 8%.
Higher discontinuation rates due to side effects raise safety concerns for long-term use.
Novo Nordisk's CagriSema faced disappointing trial results, causing a 16.5% stock drop.
Analysts criticized CagriSema versus Eli Lilly's tirzepatide, while Novo Nordisk's CEO remains optimistic.

1 of 1

Story summary

Eli Lilly's GLP-1 pill orforglipron achieved greater weight loss than semaglutide in a clinical trial, up to 8%.
Higher discontinuation rates due to side effects raise safety concerns for long-term use.
Novo Nordisk's CagriSema faced disappointing trial results, causing a 16.5% stock drop.
Analysts criticized CagriSema versus Eli Lilly's tirzepatide, while Novo Nordisk's CEO remains optimistic.